Erik Harris - 19 Jun 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP & Chief Commercial Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
19 Jun 2023
Net transactions value
-$14,701
Form type
4
Filing time
21 Jun 2023, 18:17:06 UTC
Previous filing
05 Jun 2023
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $14,701 -305 -0.53% $48.20 57,281 19 Jun 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 Includes 242 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.